Dermatitis Research Articles

Passive Smoking - Effects of Second-Hand Smoke on Oral Health

Worldwide, smoking poses a serious threat to public health. Numerous research has examined how active smoking affects health, and the overall harmful effects of active smoking are widely acknowledged. In contrast, it's unclear how passive smoking affects your health. A number of disorders, including female breast cancer, allergic rhinitis, allergic dermatitis, and food allergies, have been linked to smoking, both actively and passively. The typical oral and nasopharyngeal flora are altered by passive smoking, which increases the risk of upper airway infection. In addition to producing severe periodontitis, implant failure, gingival pigmentation in children and adults, primary and permanent tooth decay, and tooth loss, it can impair alveolar bone density. But research on the effects of passive smoking on health has not been fully compiled and is still mainly inconclusive. Consequently, the total systemic and oral negative consequences of passive smoking exposure are the focus of this review.

Antibacterial and Antiallergic Effects of Three Tea Extracts on Histamine-Induced Dermatitis.

Atopic dermatitis (AD) is a persistent and recurrent inflammatory skin condition with a genetic basis. However, the fundamental reasons and mechanisms behind this phenomenon remain incompletely understood. While tea extracts are known to reduce histamine-induced skin allergies and inflammation, the specific mechanisms by which various types of Chinese tea provide their protective effects are still not fully elucidated. In this study, a model of skin itching induced by histamine is used to explore the functions and mechanisms of three types of tea extract (Keemun black tea (HC), Hangzhou green tea (LC), and Fujian white tea (BC)) in alleviating histamine-induced dermatitis. The components of three tea extracts are identified by UPLC-Q-TOF-MS, and we found that their main components are alkaloids, fatty acyls, flavonoids, organic acids, and phenols. The inhibitory effects of three types of tea extract on Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) in skin injury are investigated by MIC and flow cytometry. The three types of tea extract have an inhibitory effect on the growth of bacterial flora, with HC showing the best inhibitory activity. The effect of the three types of tea extract on histamine-induced dermatitis is also evaluated. Furthermore, itchy skin experiments, HE staining, toluidine blue staining, and immunohistochemical staining of mouse skin tissues were performed to determine the variations of scratching, epidermal thickness, mast cell number, IL-1β, and NGF content after the administration of the tea extracts. The three types of tea extracts all alleviate and inhibit skin itching, epidermal hyperplasia, and allergic dermatitis. BC effectively alleviates epidermal hyperplasia caused by skin allergies, and LC significantly downregulates NGF. HC reduces histamine-induced mast cell infiltration and downregulates IL-1β to alleviate skin itching. Consequently, tea emerges a potent natural product that can inhibit the growth of skin wound bacterial flora and exhibit skin repair effects on histamine-induced allergic dermatitis.

Польза элиминационной диеты из гидролизованной рыбы и рисового крахмала для диагностики неблагоприятных пищевых реакций у кошек: открытое клиническое исследование

Background: diagnosis of adverse food reaction (AFR) is based on an eight week elimination diet (ED) and is confirmed by relapse upon re-challenge with the previously fed diet. Hydrolysed EDs are commonly used for this purpose. Objective: to evaluate the commercially available hydrolysed fish protein and rice starch ED Farmina UltraHypo (FUH) for the diagnosis of feline AFR. Animals: thirty-two nonseasonally pruritic cats. Materials and methods: pruritus was assessed with a new dual Visual Analog Scale, lesions with the Scoring Feline Allergic Dermatitis scale and Quality of Life with a validated questionnaire on days 0 and 56. Short-acting corticosteroids or oclacitinib were permitted during the first six weeks. Cats showing 50% pruritus and/or lesional improvement were separately challenged with their prior diet, fish and rice. Cats not responding to the study diet were fed another hydrolysed diet for two months. Results: 25 cats completed the ED: four dropped out due to vomiting and/or diarrhoea, one owing to low palatability and two were lost to follow-up. In 17 cats, pruritus improved by >50% and these underwent dietary challenges. Of these, nine reacted to their prior diet and/or fish and/or rice and were diagnosed with AFR, while eight did not relapse (and a diagnosis of AFR was considered to be doubtful). Of the eight cats in which pruritus did not improve, four underwent a second ED with no improvement. Conclusion and clinical importance: FUH may be a useful ED for the diagnosis of feline AFR, even in cats reacting to fish or rice

Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis.

Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti-inflammatory treatments is uncertain. Network meta-analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti-inflammatory eczema treatments. Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023. Included trials were within-participant or between-participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti-inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti-inflammatory. We identified 291 trials (45,846 participants), mainly in high-income countries. Most were industry-funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta-analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient-reported symptoms (40 trials, all low confidence) and clinician-reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short-term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer-term (6-60 months) topical steroids. Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti-inflammatory treatments for eczema.

Ectozoans of dogs and cats

The purpose of the study is to analyze the species composition and distribution of ectoparasites of dogs and cats on the territory of the Russian Federation. Research objectives: to study the epizootic situation regarding ectoparasites of dogs and cats on the territory of the Russian Federation. Ectoparasites of dogs and cats are widespread in the Russian Federation and pose the greatest danger as carriers of pathogens of infectious and invasive diseases. Depending on the region, the species composition and abundance of ectoparasites varies significantly. Thus, in Moscow, aphanipterosis (46–62%), otodectosis in cats (34–38%) and demodicosis in dogs (39%) were more often recorded. When examining dogs in Tyumen with diseases of the skin and hair, skin diseases of parasitic etiology were recorded in 33.86% of all examined animals. Aphanipteriosis was detected more often – 28.55%, otodectosis – 21.9%, flea allergic dermatitis – 14.65%, cheyletiosis – 13.2%, demodicosis – 12.6%, sarcoptic mange – 9.1%. A study of dogs and cats in Novosibirsk identified 6 types of parasites: Ctenocephalides canis, Otodectes cynotis, Demodex canis, Notoedres cati, Sarcoptes canis and Cheyletiella jascuri. Among cats and dogs. the most common were: aphanipterosis 4.8%, otodectosis 1.9%, demodicosis 0.23%, notoedrosis 0.14%, sarcoptic mange 0.09% and cheyletiellosis 0.3%. In the Nizhny Novgorod region, dogs and cats were diagnosed with infestation of two types of fleas (Ctenocephalides felis, C. canis), one type of lice-eater (Trichodectes canis), in addition, the following were found on the animals’ bodies: dog louse (Linognathus setosus), ixodid ticks Dermacentor reticulates, D. marginatus and I. ricinus. Thus, aphanipterosis (4.78–62.0%) and demodicosis (2.52–39.0%) are more often recorded in dogs; trichodectosis (0.64–4.2%) and ixodid ticks (9.75%) are less common. –18.0%), sarcoptic mange (1.0–9.1%), otodectosis (0.17–1.94%), and in cats – otodectosis (34–63%), notoedrosis (0.31–8.9%) and cheyletiellosis (0.27%).

Performance of applications of Ophytrium-containing mousse with or without shampoo in cats with pruritic and irritated skin: a multicentre prospective field trial.

This study aimed to evaluate the performance of a protocol in which topical products (DOUXO S3 CALM Shampoo and Mousse; Ceva Santé Animale) containing Ophytrium were applied to cats to help manage feline atopic syndrome (FAS). A total of 23 client-owned cats with a history of FAS and presenting irritated skin and pruritus were recruited for this study. The cats were either shampooed or moussed on day 0 (D0) and then moussed every 48-72 h for 3 weeks. On D0, D7 and D21, clinical signs were assessed using the validated scoring system, Scoring Feline Allergic Dermatitis (SCORFAD). Pruritus was graded by the owner using an adapted dual visual analogue scale (Pruritus Visual Analog Scale for Cats [VAScat]). Veterinarians also assessed pruritus intensity and frequency, and provided a subjective assessment of global skin condition and of improvements in each cat's condition. On D21, all questionnaires were collected from both veterinarians and owners. Among the 19 cats that completed the study, the SCORFAD and VASmax (maximum value of VAScat, either scratching or licking) scores improved by ⩾50% in 63.2% and 38.9% of animals, respectively. Mean SCORFAD values decreased significantly between D0 and D21 (from 6.2 to 2.8, P <0.05). Similarly, mean VASmax values decreased significantly between D0 and D21 (from 7.4 to 4.3, P <0.05). Overall, veterinarians assessed the improvement as satisfactory, good or excellent in 18/19 (94.7%) cases. The protocol was considered efficient and practical by 18/19 (94.7%) and 19/19 (100%) owners, respectively, and the resulting good condition of skin and coat was emphasised by 15/19 (78.9%) owners. This topical protocol with Ophytrium-containing mousse and shampoo was well tolerated. The products were effective in reducing skin irritation and discomfort quickly and significantly in cats with skin irritation and pruritus, yielding high satisfaction levels among both veterinarians and owners.

Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature.

MEK inhibitors cause a wide spectrum of mucocutaneous toxicities which can delay or interrupt life-saving therapy. To summarize the morphology, incidence, and clinical presentation of mucocutaneous toxicities from MEK inhibitors via a scoping review of the literature. We conducted a scoping review of the published literature, including clinical trials, retrospective and prospective studies, reviews, and case reports and series. All included literature was analyzed by a panel of pediatric and adult oncodermatologists. Of 1626 initial citations, 227 articles met final inclusion criteria. Our review identified follicular reactions, ocular toxicities, xerosis, eczematous dermatitis, edema, and paronychia as the most common mucocutaneous side effects from MEK inhibitor therapy. Grade 1 and 2 reactions were the most prevalent and were typically managed while continuing treatment; however, grade 3 toxicities requiring dose reductions or treatment interruptions were also reported. Mucocutaneous toxicities to MEK inhibitor therapy are common and most often mild in severity. Early recognition and treatment can mitigate disruptions in oncologic therapy.

Can Breastfeeding Prevent Long-Term Overweight and Obesity in Children? A Population-Based Cohort Study.

The aims of this study were to assess the impact of exclusive breastfeeding up to 6 months of age on reducing the incidence of overweight and obesity in children up to 10 years of age and to estimate the annual incidence of obesity and overweight in the study population. Our retrospective cohort analysis using electronic health records included children from zero to ten years old, born between 1 January 2006 and 31 December 2022, followed up at the Unidade Local de Saúde de Matosinhos (ULSM). Information on their comorbidity history was collected, and positive or negative control results were defined. In the first year of life, around 29% of the children on exclusive breastfeeding were obese and 20% were overweight. This trend was reversed by the age of 9. Asthma and allergic rhinitis were used as positive control outcomes and allergic dermatitis as a negative control outcome. There seems to be no relationship between exclusive and non-exclusive breastfeeding and the development of overweight or obesity at the age of 10. The results showed that breastfeeding is associated with a lower risk of asthma in the future.

Identification of IgE-mediated sensitization in children by enzyme immunoassay and immunofluorescence methods

The goal of research was to determine the frequency of detection and the structure of causally significant sensitization to the main groups of allergens in children with allergic diseases in Siberia when evaluating the results by enzyme immunoassay and immunofluorescence analysis. We researched 968 children with allergic rhinitis, bronchial asthma, urticaria, and/or allergic dermatitis undergoing treatment at the Consultative and Diagnostic Center for Allergology and Immunology, GDKB No. 2 named after V.P. Bisyarina of Omsk. Blood serum samples were diagnosed in the laboratory of clinical immunology. Also, the allergen-specific IgE concentrations were determined for 109 allergens, including food allergens (milk, egg, meat, fish, cereals, fruits, vegetables), household allergens (epidermal pets, dust and house dust mites, molds), and inhaled antigens (grass, trees). Analysis of 435 children was carried out by enzyme immunoassay, and 533 children by indirect immunofluorescence. The research revealed the predominance in children with allergic diseases in Siberia of IgE-mediated sensitization to household allergens, which were detected in 33.7% of the examined. IgE-mediated sensitization to inhalation and food allergens was 1.5 times less common. According to our research, the most common causative allergen among households was house dust (90%), dandruff and animal epithelium (86%), house dust mites (13.5%), and molds (1.4%). The most common causative allergen among pollen was tree allergens (47.8%), cereals (23.5%) and weeds (20.1%). The presence of multivalent sensitization with a predominant combination of household and respiratory allergens and a rarer combination of household and food allergens has been experimentally established.

Malnutrition and Allergies: Tipping the Immune Balance towards Health.

Malnutrition, which includes macro- and micronutrient deficiencies, is common in individuals with allergic dermatitis, food allergies, rhinitis, and asthma. Prolonged deficiencies of proteins, minerals, and vitamins promote Th2 inflammation, setting the stage for allergic sensitization. Consequently, malnutrition, which includes micronutrient deficiencies, fosters the development of allergies, while an adequate supply of micronutrients promotes immune cells with regulatory and tolerogenic phenotypes. As protein and micronutrient deficiencies mimic an infection, the body's innate response limits access to these nutrients by reducing their dietary absorption. This review highlights our current understanding of the physiological functions of allergenic proteins, iron, and vitamin A, particularly regarding their reduced bioavailability under inflamed conditions, necessitating different dietary approaches to improve their absorption. Additionally, the role of most allergens as nutrient binders and their involvement in nutritional immunity will be briefly summarized. Their ability to bind nutrients and their close association with immune cells can trigger exaggerated immune responses and allergies in individuals with deficiencies. However, in nutrient-rich conditions, these allergens can also provide nutrients to immune cells and promote health.

A green solution for eliminating methylene blue and crystal violet dyes using eco-friendly zinc oxide nanoparticles synthesized from Dracaena trifasciata

Modern technological development has unavoidably resulted in more pollution, especially in aquatic environments. While extensively utilized in various industries, cationic dyes pose a significant threat to both the environment and human health, ranking among the most hazardous pollutants. When exposed to these dyes, one may experience skin irritation and allergic dermatitis because they are frequently mutagenic, toxic, carcinogenic, and resistant to biodegradation. The continued release of these dyes into the environment exacerbates human health and ecosystem concerns. This work investigates the possibility of eco-friendly zinc oxide nanoparticles, which are produced by the co-precipitation method from leaf extracts of the Dracaena trifasciata plant, also referred to as snake plant, for the elimination of the cationic dyes methylene blue and crystal violet. This work presents a novel approach for synthesizing eco-friendly zinc oxide nanoparticles using leaf extract from Dracaena trifasciata. To examine the eco-friendly zinc oxide nanoparticles, characterization studies were carried out using various instrumental methods. The best conditions for removing methylene blue and crystal violet were found through batch adsorption investigations, which produced removal percentages of 86 % and 88 %, respectively, under specific conditions. The eco-friendly zinc oxide nanoparticles achieved maximum adsorption capacity and effective removal of methylene blue and crystal violet dyes under the following conditions: a pH value of 10, nanoparticle concentration of 0.06 g, reaction time of 50 min, dye concentration of 50 mg/L, and reaction temperature of 40 °C. Isotherm investigations demonstrated that the adsorption of methylene blue dye by eco-friendly zinc oxide nanoparticles followed the Temkin isotherm model, whereas the adsorption of crystal violet dye followed the Freundlich isotherm model. The kinetic parameters describing the adsorption of methylene blue and crystal violet dye onto eco-friendly zinc oxide nanoparticles were identified as pseudo-first-order and Elovich models, respectively. Following the above-mentioned studies, eco-friendly zinc oxide nanoparticles were subjected to additional characterization in order to assess their potential for wastewater treatment.

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Patch testing with Indian standard series of 20 allergens in 125 patients of chronic dermatitis and dermatoses

Objectives: Patch testing is generally done in cases of allergic contact dermatitis to find the offending allergen/s. It has been less reported in patients clinically presenting as non-eczematous contact reactions such as lichen planus, lichenoid eruption, lichen planus pigmentosus and facial melanosis overlap. In addition, it may give clues to the sensitizers leading to chronic, recurring dermatitis and overlap of dermatoses in the form of systemic contact dermatitis. The aim of the present study was to identify the sensitizer/s with patch testing in patients presenting with non-eczematous contact reactions as well as chronic, relapsing dermatitis and overlap of dermatoses. Material and Methods: In the present study, patch testing was done using the Indian standard series in 125 cases presenting clinically as lichen planus, lichen planus pigmentosus, facial melanosis, cheilitis, mucosal lichen planus and vulvar dermatitis, in addition to cases of chronic and recurrent dermatitis such as nummular eczema, lichenoid eruption, pompholyx, photo aggravated dermatitis, air borne contact and hand and feet dermatitis. Results: The tests were positive in 102 (81.6%) patients, negative in 16, doubtful in 3 and invalid in 4 patients. Positive results were found in 100% cases of photo aggravated dermatitis and chronic dermatitis of hands/feet dermatitis and 76% cases of facial melanosis and lichen planus pigmentosus overlap, 88.9% cases of nummular eczema, 81.8% cases of lichenoid eruption, 75% cases of lichen planus, 57% cases of atopic eczema, 66.6% cases of pompholyx, and 100% of mucosal lichen planus. Test for nickel was positive in 40 (32%) cases, parthenium in 37 (29.6%), cobalt in 23 (18.4%), fragrance in 19 (15.2%), paraphenylenediamine in 17 (13.6%), paraben in 9 (7.2%) and neomycin in 5 (4%) cases, either alone or in combination. In the present study, in addition to eczematous dermatoses, non-eczematous conditions such as lichen planus, lichenoid eruption, lichen planus pigmentosus and facial melanosis also showed positive results on patch testing. Conclusion: Patch testing should be considered in patients presenting with chronic and recurrent dermatitis and overlap of more than one type of dermatoses. Identification and elimination of culprit allergens can help in achieving long term remission in these chronic conditions.

AKT answer relating to childhood eczema treatment

AKT answer relating to childhood eczema treatment

AKT question relating to childhood eczema treatment

AKT question relating to childhood eczema treatment

Evaluating the Efficacy of Homeopathic Treatments in the Management of Eczema: A Comprehensive Review

Background: Eczema, a chronic inflammatory skin condition, significantly affects patients' quality of life. Conventional treatments, while often effective, can have limitations and adverse effects. Homeopathy, an alternative medical system, has been proposed as a complementary approach for eczema management. This review aims to evaluate the efficacy of homoeopathic treatments in managing eczema. Methods: A comprehensive literature review was conducted using online databases. Studies were selected based on predefined inclusion and exclusion criteria, focusing on randomised controlled trials, observational studies, and patient-reported outcomes. Data extraction and quality assessment were performed systematically, and results were synthesised using qualitative and quantitative methods. Results: The review identified diverse studies exploring homoeopathic treatments for eczema. Evidence on the efficacy of homoeopathy in eczema management is mixed, with some studies reporting significant improvements in symptoms and quality of life, while others show limited or no benefit compared to placebo. Homoeopathy offers a benefit, particularly in reducing symptom severity and improving patient satisfaction. Subgroup analyses indicated variations in response based on age, eczema severity, and individual patient characteristics. Discussion: The findings suggest that homoeopathic treatments could play a role in the holistic management of eczema, potentially enhancing patient outcomes. However, the variability in study quality and outcomes highlights the need for more rigorous research to establish definitive conclusions. Potential mechanisms of action and clinical implications are discussed, emphasizing the importance of personalized treatment approaches. Conclusion: While homoeopathy shows promise as a treatment for eczema, further high-quality studies are necessary to validate its efficacy and understand its role within a broader therapeutic context. Future research should focus on standardized methodologies and long-term effects to provide clearer guidance for clinicians and patients.

Clinical Efficacy of Huanglian Ointment in the Treatment of Chronic Eczema

Clinical Efficacy of Huanglian Ointment in the Treatment of Chronic Eczema

Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema

Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema

Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials

Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema. Both trials were randomised, double-blinded, and vehicle-controlled, with DELTA 1 being conducted at 53 trial centres in Canada, France, Germany, Italy, Poland, and the UK and DELTA 2 at 50 trial centres in Belgium, Canada, Denmark, Germany, the Netherlands, Poland, and Spain. Adults (aged ≥18 years) with moderate to severe chronic hand eczema were randomly assigned 2:1 to twice-daily delgocitinib cream 20 mg/g or cream vehicle for 16 weeks. The primary endpoint was Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) treatment success at week 16, defined as IGA-CHE score of 0 (clear) or 1 (almost clear, defined as only barely perceptible erythema). Efficacy and safety were assessed in all patients who were exposed to trial treatment. These trials are registered with ClinicalTrials.gov, NCT04871711 and NCT04872101. Between May 10, 2021, and Oct 31, 2022, 487 patients (181 male and 306 female) were enrolled in DELTA 1; between May 25, 2021, and Jan 6, 2023, 473 patients (161 male and 312 female) were enrolled in DELTA 2. 325 patients in DELTA 1 and 314 in DELTA 2 were assigned to delgocitinib cream; 162 patients in DELTA 1 and 159 in DELTA 2 were assigned to cream vehicle. At week 16, a greater proportion of delgocitinib-treated patients versus cream vehicle patients had IGA-CHE treatment success (64 [20%] of 325 vs 16 [10%] of 162 in DELTA 1 and 91 [29%] of 313 vs 11 [7%] of 159 in DELTA 2; both trials p≤0·0055). The proportion of patients who reported adverse events was similar with delgocitinib (147 [45%] of 325 in DELTA 1 and 143 [46%] of 313 in DELTA 2) and the cream vehicle (82 [51%] of 162 in DELTA 1 and 71 [45%] of 159 in DELTA 2). Most frequent adverse events occurring in at least 2% of patients were similar in both treatment groups and included COVID-19 and nasopharyngitis. Overall, delgocitinib cream showed superior efficacy versus cream vehicle and was well tolerated over 16 weeks. These results support the clinical benefit of delgocitinib cream as a potential treatment option for patients with moderate to severe chronic hand eczema, who are unable to adequately control their disease with basic skin care practices and topical corticosteroids. LEO Pharma.

Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

This study investigated the incidence and progression of (hyper)eosinophilia in patients with atopic dermatitis (AD) treated with dupilumab, using data from the TREAT NL registry cohort. In total, 38.5% of patients had (hyper)eosinophilia at baseline and/or during dupilumab treatment. (Hyper)eosinophilia was present at baseline in 43 (55.8%) patients and developed in 34 (44.2%) patients during treatment. Eosinophilia was transient, peaking at 6 months and normalizing by 18–24 months. One patient discontinued dupilumab due to persistent hypereosinophilia, but generally, eosinophilia did not affect treatment outcomes. In conclusion, dupilumab is found viable for patients with AD regardless of baseline eosinophilia, with temporary increases in eosinophil counts that are often not clinically significant.